Topics:
Medical Oncology • Myelodysplastic Syndromes
When would you use oral cedazuridine/decitabine as opposed to parenteral HMAs to treat intermediate or high risk MDS?
Garcia-Manero et al., PMID 32285126
Given the convenience of oral therapy, would you depend on the patient's ability to safely comply with the schedule and administration instructions of oral therapies, insurance coverage, etc, in order to choose?
Are there other disease-specific characteristics that you take into consideration?
Answer from: Medical Oncologist at Academic Institution
Oral cedazuridine/decitabine was approved in the US for the treatment of intermediate and high risk MDS and CMML based on its equivalent exposure to 20 mg/m2 of IV decitabine in Phase 3 study. Drug related toxicities and response rates were as would be historically expected for IV decitabine (full d...
Sign in or Register to read more